MedTrace Logo

Regulatory Request NIS in Korea

NCT03642717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 658

Last updated 2021-05-21

Study results available
· View outcomes & findings →

Summary

To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

JARDIANCE DUO®

empagliflozin and metformin

Sponsors & Collaborators

Principal Investigators

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-21
Primary Completion
2020-04-30
Completion
2020-04-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642717 on ClinicalTrials.gov